INTERCOVID is a large, multi-national, prospective cohort study with the aim of assessing the effect of COVID-19 in pregnancy on maternal, fetal and neonatal outcomes worldwide. 

In 2020, when the COVID-19 outbreak began, there was very little information knows about the virus. Although it was generally believed that pregnant women with COVID-19 were at similar risk to the general population, there were limited data available, principally from small case series without controls, which cannot answer fundamental questions relating to the effects of the disease in pregnancy. To address this knowledge gap, the INTERCOVID study was set up to gather information quickly and at scale to optimise maternal and newborn care, reduce maternal anxiety, inform decision-making about the allocation of resources, and guide the process toward social adaptation. 

The study commenced field preparations on April 20th 2020 and recruitment started immediately, with 62 medical institutions in 29 countries agreeing to participate. 

In 2022, a second round of data collection commenced, INTERCOVID-2022, to investigate the effects of COVID-19 on maternal and perinatal outcomes during pregnancy, and evaluate vaccine effectiveness, with omicron (B.1.1.529) as the variant of concern.

Yellow = Collaborating institutions                           Red = INTERCOVID sites